製品番号: HY-14944

Homoharringtonine

Name: Homoharringtonine
Brand: MedChemExpress
SKU: HY-14944
Price: 70.00 USD
Availability: InStock
Rating: 5 (37 reviews)

(別名: HHT; Omacetaxine mepesuccinate; ホモハリントニン)

37 Cited Publications

カスタマーレビュー

Based on 37 publication(s) in Google Scholar

Homoharringtonine (Omacetaxine mepesuccinate;HHT) is a cytotoxic alkaloid with antitumor properties which acts by inhibiting translation elongation.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度 : 99.75%
CAS 番号: 26833-87-4
分子式: C₂₉H₃₉NO₉
分子量:545.62

保管条件:

4°C, protect from light

* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

Homoharringtonine 構造式

CAS 番号: 26833-87-4

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 体内実験
- 臨床実験
化学情報
Publications (37)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

Homoharringtonine (Omacetaxine mepesuccinate;HHT) is a cytotoxic alkaloid with antitumor properties which acts by inhibiting translation elongation.

IC₅₀ & Target

^[1]

STAT3

STAT アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
4T1	IC₅₀	0.06 μM Compound: 1; HHT	Antiproliferative activity against mouse 4T1 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay Antiproliferative activity against mouse 4T1 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay	[PMID: 36242991]
A204	IC₅₀	0.004 μM Compound: 1; HHT	Antiproliferative activity against human A204 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay Antiproliferative activity against human A204 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay	[PMID: 36242991]
A549	IC₅₀	0.03 μM Compound: Homoharringtonine	Cytotoxicity against human A549 cells assessed as reduction of cell growth by SRB method Cytotoxicity against human A549 cells assessed as reduction of cell growth by SRB method	[PMID: 18782668]
A549	IC₅₀	18.28 nM Compound: HHT	Inhibition of Nuclear factor erythroid 2-related factor 2 5'-untranslated region guanine-rich DNA sequence in human A549 cells harboring ARE-GFP-Luc assessed as reduction in ARE-luciferase activity after 24 hrs by firefly luciferase reporter gene assay Inhibition of Nuclear factor erythroid 2-related factor 2 5'-untranslated region guanine-rich DNA sequence in human A549 cells harboring ARE-GFP-Luc assessed as reduction in ARE-luciferase activity after 24 hrs by firefly luciferase reporter gene assay	[PMID: 31270017]
A549	IC₅₀	31.6 nM Compound: homoharringtonine	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 31916761]
BaF3	IC₅₀	0.081 μM Compound: 1; HHT	Antiproliferative activity against mouse BaF3 cells expressing Bcr/Abl-T315I mutant assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay Antiproliferative activity against mouse BaF3 cells expressing Bcr/Abl-T315I mutant assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay	[PMID: 36242991]
Caco-2	CC₅₀	1.72 μM Compound: HOMOHARRINGTONINE	Toxicity against Caco-2 cells determined at 48 hours by intracellular ATP concentration using the CellTiter-Glo Luminescent Cell Viability Assay Toxicity against Caco-2 cells determined at 48 hours by intracellular ATP concentration using the CellTiter-Glo Luminescent Cell Viability Assay	10.21203/rs.3.rs-23951/v1
Caco-2	IC₅₀	4.71 μM Compound: HOMOHARRINGTONINE	Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells after 48 hours by high content imaging Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells after 48 hours by high content imaging	10.21203/rs.3.rs-23951/v1
HCT-116	IC₅₀	0.013 μM Compound: 1; HHT	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay	[PMID: 36242991]
HeLa	IC₅₀	0.4 μM Compound: Homoharringtonine	Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 33905250]
HeLa	IC₅₀	1.7 μM Compound: HHT	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth measured after 68 hrs by MTS assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth measured after 68 hrs by MTS assay	[PMID: 35148094]
HepG2	IC₅₀	34.5 nM Compound: homoharringtonine	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 31916761]
HL-60	IC₅₀	0.013 μM Compound: 1; HHT	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay	[PMID: 36242991]
HL-60	IC₅₀	0.02 μM Compound: homoharringtonine	Cytotoxicity against human HL60 cells assessed as growth inhibition after 72 hrs by Alamar Blue assay Cytotoxicity against human HL60 cells assessed as growth inhibition after 72 hrs by Alamar Blue assay	10.1039/C0MD00241K
HL-60	IC₅₀	0.022 μM Compound: HHT	Antiproliferative activity against human HL60 cells after 62 hrs by MTS assay Antiproliferative activity against human HL60 cells after 62 hrs by MTS assay	[PMID: 29286665]
HL-60	IC₅₀	21.8 nM Compound: HHT	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth measured after 68 hrs by MTS assay Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth measured after 68 hrs by MTS assay	[PMID: 35148094]
Huh-7	IC₅₀	0.04 μM Compound: 1; HHT	Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay	[PMID: 36242991]
K562	IC₅₀	0.014 μM Compound: 1; HHT	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay Antiproliferative activity against human K562 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay	[PMID: 36242991]
K562	IC₅₀	21 nM Compound: 10	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth Antiproliferative activity against human K562 cells assessed as inhibition of cell growth	[PMID: 36155354]
K562	IC₅₀	43.89 ng/mL Compound: HHT	Antiproliferative activity against human K562 cells assessed as cell growth inhibition Antiproliferative activity against human K562 cells assessed as cell growth inhibition	[PMID: 35551036]
KB	ED₅₀	3.9 μg/mL Compound: Homoharringtonine	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 7130986]
KB	IC₅₀	0.004 μM Compound: Homoharringtonine	Cytotoxicity against human KB cells assessed as reduction of cell growth by SRB method Cytotoxicity against human KB cells assessed as reduction of cell growth by SRB method	[PMID: 18782668]
L02	IC₅₀	0.064 μM Compound: 1; HHT	Cytotoxicity against human HL7702 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay Cytotoxicity against human HL7702 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay	[PMID: 36242991]
MCF7	IC₅₀	0.87 nM Compound: 10	Cytotoxicity against human MCF7 cells assessed as reduction in protein synthesis Cytotoxicity against human MCF7 cells assessed as reduction in protein synthesis	[PMID: 28850227]
MDA-MB-453	IC₅₀	0.021 μM Compound: 1; HHT	Antiproliferative activity against human MDA-MB-453 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay Antiproliferative activity against human MDA-MB-453 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay	[PMID: 36242991]
MOLT-4	IC₅₀	0.007 μM Compound: 1; HHT	Antiproliferative activity against human MOLT-4 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay Antiproliferative activity against human MOLT-4 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay	[PMID: 36242991]
MV4-11	IC₅₀	0.005 μM Compound: 1; HHT	Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay	[PMID: 36242991]
NCI-H1299	IC₅₀	0.022 μM Compound: 1; HHT	Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay	[PMID: 36242991]
NCI-H1975	IC₅₀	0.022 μM Compound: 1; HHT	Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay	[PMID: 36242991]
NCI-H716	IC₅₀	0.065 μM Compound: 1; HHT	Antiproliferative activity against human NCI-H716 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay Antiproliferative activity against human NCI-H716 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay	[PMID: 36242991]
OCI-Ly3	IC₅₀	0.005 μM Compound: 1; HHT	Antiproliferative activity against human OCILY3 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay Antiproliferative activity against human OCILY3 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay	[PMID: 36242991]
P388	IC₅₀	0.017 μg/mL Compound: 4	Antileukemic activity against P-388 leukemia cells. Antileukemic activity against P-388 leukemia cells.	10.1016/0960-894X(96)00302-2
Panel NCI-60 (60 carcinoma cell lines)	GI₅₀	4.4 nM Compound: Homoharringtonine	Growth inhibitory activity against human cancer cell line in the NCI's anticancer drug screening program Growth inhibitory activity against human cancer cell line in the NCI's anticancer drug screening program	[PMID: 15743190]
U-937	IC₅₀	0.012 μM Compound: 1; HHT	Antiproliferative activity against human U-937 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay Antiproliferative activity against human U-937 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay	[PMID: 36242991]
Vero C1008	EC₅₀	0.06 μM Compound: 1; HHT	Antiviral activity against SARS-CoV-2 infected in African green monkey Vero E6 cells assessed as inhibition of viral replication Antiviral activity against SARS-CoV-2 infected in African green monkey Vero E6 cells assessed as inhibition of viral replication	[PMID: 33592144]

体外実験

Homoharringtonine inhibits IL-6-induced STAT3 phosphorylation in a dose- and time-dependent manner. Homoharringtonine (HHT) inhibits cells growth, cell viability and colony formation, as well as induced cell apoptosis through mitochondria pathway. The cytotoxicity of Homoharringtonine on human NSCLC cell lines is investigated, A549 (wild type EGFR) and NCI-H1975 (H1975, mutant EGFR with L858R and T790M), Gefitinib is used as a control. By MTT assay, Homoharringtonine has moderate cytotoxicity to A549 with an IC₅₀ of 3.7 μM and H1975 cells are more sensitive to Homoharringtonine with an IC₅₀ of 0.7 μM. Homoharringtonine inhibits the cell proliferation and growth of A549 cells and H1975 cells in a time- and dose-dependent manner through MTT assay. By trypan blue exclusion assay, Homoharringtonine rapidly reduces viable A549 and H1975 cells in a dose- and time-dependent manner. Homoharringtonine significantly inhibits the clonogenic ability of A549 and H1975 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Homoharringtonine (10 mg/kg; 5 times weekly; 3 weeks) exhibits antitumor activity in H1975 xenograft nude mouse models^[1].
Homoharringtonine (1 mg/kg; subcutaneous injection; twice daily; 7 days) shows antitumor activity in MDA-MB-231 xenograft nude mouse models^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Nude immunodeficient mice aged 6-8 weeks old treated H1975 cells^[1]
Dosage:

10 mg/kg
Administration:

5 times per week; 3 weeks
Result:

Significantly repressed tumor growth, and there was no apparent side effect as indicated by no reduction in mice body weight.
Downregulated the phosphorylation of STAT3 and the expression of MCL1 in tumor tissues.

Animal Model:

Swiss nu/nu female mice aged 6 weeks old treate MDA-MB-231 cells^[1]
Dosage:

1 mg/kg
Administration:

Subcutaneous injection (s.c.); bi-daily; 7 days.
Result:

Reduced the mean tumor volume by 36.5% in the treated group compared to the control group at day 10, with minimal change in animal weight, indicating significant tumor growth inhibition without general toxicity.

臨床実験

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

化学情報

CAS 番号 26833-87-4
性状 Solid
分子量 545.62
分子式 C₂₉H₃₉NO₉
Color Off-white to yellow
SMILES

[H][C@@]12[C@](CCC3)(C=C(OC)[C@]2(OC([C@](CCCC(O)(C)C)(O)CC(OC)=O)=O)[H])N3CCC4=CC5=C(OCO5)C=C14
別名

HHT; Omacetaxine mepesuccinate; ホモハリントニン
Structure Classification
- Alkaloids
- Pyrrole Alkaloids
Initial Source
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, protect from light

* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

Publications (37)

All WBIFMicrobiological AssayRT-PCR

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]

2025 Dec 15;10(1):406. PMID: 41392286
Cell

An E3 ligase network engages GCN1 to promote the degradation of translation factors on stalled ribosomes. [Abstract]

2023 Jan 19;186(2):346-362.e17. PMID: 36638793
Cell Res

SMYD5 is a ribosomal methyltransferase that catalyzes RPL40 lysine methylation to enhance translation output and promote hepatocellular carcinoma. [Abstract]

2024 Sep;34(9):648-660. PMID: 39103523
Nat Commun

Increased translation driven by non-canonical EZH2 creates a synthetic vulnerability in enzalutamide-resistant prostate cancer. [Abstract]

2024 Nov 20;15(1):9755. PMID: 39567499
Nat Commun

A high-throughput screen for TMPRSS2 expression identifies FDA-approved compounds that can limit SARS-CoV-2 entry. [Abstract]

2021 Jun 23;12(1):3907. PMID: 34162861

Homoharringtonine purchased from MedChemExpress. Usage Cited in: Nat Commun. 2021 Jun 23;12(1):3907. [Abstract]

Immunoblot analysis of endogenous TMPRSS2 protein level in Caco-2 cells treated for 18 h with HHT.

Homoharringtonine purchased from MedChemExpress. Usage Cited in: Nat Commun. 2021 Jun 23;12(1):3907. [Abstract]

Effects of HHT (18h) or HFG on pseudoviral-mediated GFP expression, determined by immunostaining, scale bar = 500 µm.

Homoharringtonine purchased from MedChemExpress. Usage Cited in: Nat Commun. 2021 Jun 23;12(1):3907. [Abstract]

SARS-CoV-2 pseudoviral infection of primary human bronchial epithelial cells in the presence of increasing concentrations of HHT (incubated for 1 h with pseudovirus).

Homoharringtonine purchased from MedChemExpress. Usage Cited in: Nat Commun. 2021 Jun 23;12(1):3907. [Abstract]

qPCR analysis of viral RNA in culture supernatant of Calu-3 cells under titration of HFG or HHT at 72 h following an initial infection of SARS-CoV-2 using an MOI of 0.01. Calu-3 cells were pretreated with Homoharringtonine (HHT) for 24 h. Media was exchanged, and cells were exposed to SARS-CoV-2 virus for 75 min, then exchanged for fresh media replenished with HHT. Supernatant samples were taken at 48 and 72 h for qPCR analysis of viral RNA.
Cell Discov

Single-cell multiomics analysis reveals regulatory programs in clear cell renal cell carcinoma. [Abstract]

2022 Jul 19;8(1):68. PMID: 35853872
Redox Biol

IL-13 facilitates ferroptotic death in asthmatic epithelial cells via SOCS1-mediated ubiquitinated degradation of SLC7A11. [Abstract]

2024 May:71:103100. PMID: 38484644
J Exp Clin Cancer Res

Genomic profiling of a collection of patient-derived xenografts and cell lines identified ixabepilone as an active drug against chemo-resistant osteosarcoma. [Abstract]

2025 Jul 8;44(1):195. PMID: 40624718
J Control Release

In situ therapeutic vaccines for leukemia by chemo-nanoadjuvant therapy. [Abstract]

2025 Jul 10:383:113851. PMID: 40389164
Pharmacol Res

Time-dependent proteomics and drug response in expanding cancer cells. [Abstract]

2024 Jun:204:107208. PMID: 38729587
Pharmacol Res

Cardamonin retards progression of autosomal dominant polycystic kidney disease via inhibiting renal cyst growth and interstitial fibrosis. [Abstract]

2020 May:155:104751. PMID: 32151678
Cell Commun Signal

Activation of c-Myc confers resistance to venetoclax via inhibition of Bim in t(8;21)-positive acute myeloid leukemia. [Abstract]

2026 Jun 11. PMID: 42277819
J Transl Med

Spermatogenesis associated serine rich 2 like plays a prognostic factor and therapeutic target in acute myeloid leukemia by regulating the JAK2/STAT3/STAT5 axis. [Abstract]

2023 Feb 11;21(1):115. PMID: 36774517
Oncogene

Inhibitor of DNA binding 2 (ID2) regulates the expression of developmental genes and tumorigenesis in ewing sarcoma. [Abstract]

2022 May;41(20):2873-2884. PMID: 35422476
Oncogene

The translational repressor 4E-BP1 regulates RRM2 levels and functions as a tumor suppressor in Ewing sarcoma tumors. [Abstract]

2021 Jan;40(3):564-577. PMID: 33191406
Pharmaceutics

Drug Repurposing for the Identification of Compounds with Anti-SARS-CoV-2 Capability via Multiple Targets. [Abstract]

2022 Jan 12;14(1):176. PMID: 35057070
Virulence

2026 Dec;17(1):2707775. PMID: 42482630
Biomed J

Repurposing old drugs as antiviral agents for coronaviruses. [Abstract]

2020 Aug;43(4):368-374. PMID: 32563698
Cancer Biol Ther

Caspase 3-specific cleavage of ubiquitin-specific peptidase 48 enhances drug-induced apoptosis in AML. [Abstract]

2025 Dec;26(1):2459426. PMID: 39878157
Sci Rep

Sensitivity to an inhibitor of translation elongation in solid and hematologic cancers. [Abstract]

2025 Jul 1;15(1):21328. PMID: 40596490
Biol Proced Online

Establishment of a mouse lung cancer organoid model and its applications for therapeutic screening. [Abstract]

2025 Jun 16;27(1):21. PMID: 40524168
Sci Rep

Elucidating host cell response pathways and repurposing therapeutics for SARS-CoV-2 and other coronaviruses. [Abstract]

2022 Nov 5;12(1):18811. PMID: 36335206
Comput Struct Biotechnol J

Severe fever with thrombocytopenia syndrome virus (SFTSV)-host interactome screen identifies viral nucleoprotein-associated host factors as potential antiviral targets. [Abstract]

2021 Oct 1:19:5568-5577. PMID: 34712400
Antiviral Res

Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. [Abstract]

2020 Jun:178:104786. PMID: 32251767
J Med Virol

Inhibitory effects of homoharringtonine on foot and mouth disease virus in vitro. [Abstract]

2019 Sep;91(9):1595-1601. PMID: 31032977
Arch Biochem Biophys

Homoharringtonine inhibits melanoma cells proliferation in vitro and vivo by inducing DNA damage, apoptosis, and G2/M cell cycle arrest. [Abstract]

2021 Mar 30:700:108774. PMID: 33548212
Am J Cancer Res

The small-molecule drug homoharringtonine targets HSF1 to suppress pancreatic cancer progression. [Abstract]

2024 May 15;14(5):2072-2087. PMID: 38859866
World J Oncol

Characterization of Asciminib-Resistant Philadelphia Chromosome-Positive Cells. [Abstract]

2024 Apr;15(2):319-324. PMID: 38545482
bioRxiv

2026 Feb 23.
bioRxiv

2025 Nov 16.
Patent

US20240344035A1
Patent

US20240344035A1.
Biomed Pharmacother

(Homo-)harringtonine prevents endothelial inflammation through IRF-1 dependent downregulation of VCAM1 mRNA expression and inhibition of cell adhesion molecule protein biosynthesis. [Abstract]

2024 Jul:176:116907. PMID: 38865849
Heliyon

Enhancement of the IFN-β-induced host signature informs repurposed drugs for COVID-19. [Abstract]

2020 Dec;6(12):e05646. PMID: 33289002
Res Sq

A high throughput screen for TMPRSS2 expression identifies FDA-approved and clinically advanced compounds that can limit SARS-CoV-2 entry. [Abstract]

2020 Aug 14:rs.3.rs-48659. PMID: 32818215
Research Square Preprint

2020 Aug.
Oncotarget

Homoharringtonine suppresses imatinib resistance via the Bcl-6/p53 pathway in chronic myeloid leukemia cell lines. [Abstract]

2017 Jun 6;8(23):37594-37604. PMID: 28410239

Homoharringtonine purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 Jun 6;8(23):37594-37604. [Abstract]

The expression of apoptosis proteins. K562/G01 cells treated with HHT 0, 50nM, 100 nM, 200nM for 24h. Bcl-2, caspase9, caspase3 express.

溶剤 & 溶解度

体外:

DMSO : ≥ 50 mg/mL (91.64 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 1.4 mg/mL (2.57 mM; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.8328 mL

9.1639 mL

18.3278 mL

5 mM

0.3666 mL

1.8328 mL

3.6656 mL

10 mM

0.1833 mL

0.9164 mL

1.8328 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.58 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (4.58 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.58 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 1.67 mg/mL (3.06 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (287 KB)
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Cao W, et al. Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells. Sci Rep. 2015 Jul 13;5:8477 [Content Brief]

[2]. Yakhni M, et al. Homoharringtonine, an approved anti-leukemia drug, suppresses triple negative breast cancer growth through a rapid reduction of anti-apoptotic protein abundance. Am J Cancer Res. 2019 May 1;9(5):1043-1060. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	1.8328 mL	9.1639 mL	18.3278 mL	45.8194 mL
DMSO	5 mM	0.3666 mL	1.8328 mL	3.6656 mL	9.1639 mL
	10 mM	0.1833 mL	0.9164 mL	1.8328 mL	4.5819 mL
	15 mM	0.1222 mL	0.6109 mL	1.2219 mL	3.0546 mL
	20 mM	0.0916 mL	0.4582 mL	0.9164 mL	2.2910 mL
	25 mM	0.0733 mL	0.3666 mL	0.7331 mL	1.8328 mL
	30 mM	0.0611 mL	0.3055 mL	0.6109 mL	1.5273 mL
	40 mM	0.0458 mL	0.2291 mL	0.4582 mL	1.1455 mL
	50 mM	0.0367 mL	0.1833 mL	0.3666 mL	0.9164 mL
	60 mM	0.0305 mL	0.1527 mL	0.3055 mL	0.7637 mL
	80 mM	0.0229 mL	0.1145 mL	0.2291 mL	0.5727 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Bioz

Keywords

Homoharringtonine

37 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Homoharringtonine

MedChemExpress（MCE）の使用を引用している文献 Homoharringtonine

STAT アイソフォーム固有の製品をすべて表示

生物活性